Type 2 diabetes subgroups and response to glucose-lowering therapy: Results from the EDICT and Qatar studies

Medicine and Dentistry

• Combination Therapy 100%
• Glucose 83%
• Maturity Onset Diabetes of the Young 83%
• Patient 66%
• Hemoglobin A1c 50%
• Cell Function 50%
• Insulin Resistance 50%
• Beta Cell 50%
• Patient with Type 2 Diabetes 33%
• Insulin Sensitivity 33%
• Homeostatic Model Assessment 33%
• Insulin Deficiency 33%
• Measurement 16%
• Phenotype 16%
• Research Design 16%
• Glycated Hemoglobin 16%
• Oral Glucose Tolerance Test 16%
• Pioglitazone 16%
• Insulin Release 16%
• Hyperinsulinemia 16%
• Glycon 16%
• C-Peptide 16%
• Insulin Treatment 16%
• Insulin Clearance 16%
• Insulin Sensitizing Agent 16%
• Exenatide 16%
• Cluster Analysis 16%
• Glipizide 16%
• Age 16%

Nursing and Health Professions

• Combination Therapy 100%
• Glucose 83%
• Insulin Resistance 50%
• Hemoglobin A1c 50%
• Non Insulin Dependent Diabetes Mellitus 33%
• Insulin 33%
• Body Mass 33%
• Homeostasis Model Assessment 33%
• Insulin Deficiency 33%
• Measurement 16%
• Glucose Blood Level 16%
• Drug Therapy 16%
• Cluster Analysis 16%
• Insulin Treatment 16%
• Oral Glucose Tolerance Test 16%
• Glycosylated Hemoglobin 16%
• Metformin 16%
• Insulin Sensitizing Agent 16%
• Control 16%
• Procedures 16%
• Hyperinsulinemia 16%
• Pioglitazone 16%
• Exendin 4 16%
• C Peptide 16%
• Glipizide 16%
• Insulin Clearance 16%